Bertran-Alamillo et al. revealed that AURKB is related to acquire resistance to EGFR TKIs, and AURKB can become a potential biological target for anti-EGFR therapy of NSCLC without carrying resistance mutations [32]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.